Objectives We carried out a randomized multicentre study in China to investigate whether
the clofazimine would improve the efficacy of the standardized regimen in patients with …

The inappropriate treatment of drug-susceptible tuberculosis can lead to the selection and
transmission of multidrug-resistant tuberculosis (MDR-TB), indicating resistance to at least …

Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …

The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted
in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved …

Multidrug-resistant tuberculosis (MDR-TB) presents an increasing threat to global
tuberculosis control. Many crucial management issues in MDR-TB treatment remain …

Background The programmatic management of Multidrug-resistant tuberculosis (MDR-TB) is
entirely based on a WHO recommended long-term, 18–24 month lasting treatment regimen …

Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving
treatment and there is an urgent need to scale up treatment programmes. One of the biggest …

We sought to compare the effectiveness of two World Health Organization (WHO)-
recommended regimens for the treatment of rifampin-or multidrug-resistant (RR/MDR) …

Background After a history of poor treatments for rifampin-resistant tuberculosis (RR-TB),
recent advances have resulted in shorter, more effective treatments. However, they are not …

Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To
evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a …